We use cookies for a better user experience. Read our Privacy Policy

I Agree

Bioengineered Protein Drugs Market Insights, 2017-2025

Bioengineered Protein Drugs Market (Drug Type - Monoclonal Antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, and Synazis), Therapeutic Proteins (Hormones, Cytokines, Blood Factor, Enzyme Therapy, and Thrombolytics), and Vaccines; Disease Condition - Cancer, Diabetes, Autoimmune Disorder, Infectious Disease, Hematopoiesis, CVD, and Neurodegenerative; End User - Pharmaceutical and Biotechnology Companies, CROs, and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Bioengineered protein drugs are used in the treatment of chronic diseases such as asthma and diabetes.

The global bioengineered protein drugs market is expected to grow at a compound annual growth rate (CAGR) of 7.4% during the forecast period between 2017 and 2025.

The increasing cases of chronic diseases and the extensive technological progress made by the biopharmaceuticals industry have emerged as the key growth drivers for the bioengineered protein drugs market.

Bioengineered protein drugs have minimum side effects, which could have a positive impact on its demand. Healthcare professionals have been recommending these drugs, thereby propelling the overall bioengineered protein drugs market.

global bioengineered protein drugs market

Vaccine Product Segment Anticipated to Witness Maximum Growth in Future

The global bioengineered protein drugs market is studied based on product type, region, disease condition, and end-use.

Based on product type, it is classified into vaccines, therapeutic protein, and monoclonal antibodies.

In recent times, the therapeutic protein product segment has held a major share in the overall bioengineered protein drugs market, owing to many undertakings in therapeutic product engineering field.

However, the vaccine product segment of the bioengineered protein drugs market is anticipated to be the leader, in terms of growth rate, during the forecast period because of the advancement and development in bioengineered therapeutic vaccines.

Based on disease condition, the bioengineered protein drugs market has been segmented into infectious disease, diabetes, hematopoiesis, neurodegenerative, autoimmune disorder, and cancer.

Based on end-use, the bioengineered protein drugs market has been segmented into CROs, research institutes, and pharmaceutical and biotechnology.

Asia Pacific to Witness Maximum Growth in Bioengineered Protein Drugs Market During Forecast Period

In terms of region, North America has emerged as the leader in the global bioengineered protein drugs market and is anticipated to witness strong growth, in future as well. In 2017, North America contributed a total revenue of US$ 92703.5 Mn to the overall bioengineered protein drugs market.

The rising number of chronic diseases and the introduction of technologically advanced protein therapeutics for the disease have emerged as key growth drivers for the bioengineered protein drugs market, in this region.

A TMR report projects the global bioengineered protein drugs market in North America to grow at a CAGR of 7.2% during the forecast period.

Asia Pacific, however, is anticipated to surpass North America in the global bioengineered protein drugs market, as it is anticipated to grow at a CAGR of 9% during the forecast period.

The factors driving the growth of the bioengineered protein drugs market in Asia Pacific are an increasing presence of chronic disorders, growth in healthcare facilities in several economies in this region, and huge investments by key market players.

The countries which are expected to play a leading role in Asia Pacific's growth in the market are India, South Korea, and China.

Among them, China has emerged as the major economy for the growth of the bioengineered protein drugs market because of factors such as rising geriatric population and increasing population section, who have signed up private health policies.

Europe is expected to witness slow growth in the global bioengineered protein drugs market during the forecast period because of the emergence of biosimilars in this region.

A few well-established players in the bioengineered protein drugs market include Dr. Reddy Laboratories, Johnson and Johnson, Bayer AG, and Abbott Laboratories.

Market players are making huge investments in research and development activities to produce advanced bioengineered protein drugs.

High Costs Could Hamper Growth of Bioengineered Protein Drug Market

The bioengineered protein drugs market faces its own set of challenges. One of them is the high cost of these drugs, which could have a negative impact on the demand, in turn affecting the overall market.

The high cost, along with the emergence of biosimilar drugs could also lead to a decline in demand for bioengineered protein drugs, in future.

The other challenge is the high manufacturing costs involved in the production of the bioengineered protein drug.

The global Bioengineered Protein Drugs market has been segmented into:

by Drug Type

  • Monoclonal Antibodies
    • Humira
    • Rituxan
    • Avastin
    • Herceptin
    • Remicade
    • Lucentis
    • Enbrel
    • Synazis
    • Others
  • Therapeutic Proteins
    • Hormones
    • Cytokines
      • Neupogen
      • Neulasta
      • Interferon Alpha
      • Erythropoietin Alpha
      • Interleukin
      • Others
    • Blood Factor
    • Enzyme Therapy
      • Systemic Enzyme Therapy
      • Digestive Enzyme Therapy
    • Thrombolytics
      • tPA
      • Streptokinase
      • Urokinase
  • Vaccines

by Disease Condition

  • Cancer
  • Diabetes
  • Autoimmune Disorder
  • Infectious Disease
  • Hematopoiesis
  • CVD
  • Neurodegenerative
  • Others

by End-user

  • Pharma and Biotech Companies
  • CROs
  • Academics

by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)
    • Japan
    • China
    • India
    • Australia
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA
Bioengineered Protein Drugs Market Insights, 2017-2025

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of Bioengineered Protein Drugs Market?

The global Bioengineered Protein Drugs Market was worth US$177.7 bn and is projected to reach a value of US$336.9 bn by the end of 2025

What is the anticipated CAGR of the Bioengineered Protein Drugs Market in the forecast period?

Bioengineered Protein Drugs Market is anticipated to grow at a CAGR of 7.4% during the forecast period

Which region is expected to project the highest market share in the global Bioengineered Protein Drugs Market?

North America accounted for a major share of the global Bioengineered Protein Drugs Market

What are the key driving factors for the growth of the Bioengineered Protein Drugs Market?

Bioengineered Protein Drugs Market is driven by rising prevalence of diseases, rising expenditure on healthcare and advancements in the biotech sector

Who are the key players in the global Bioengineered Protein Drugs Market?

Key players in the global Bioengineered Protein Drugs Market include ProBioGen AG, Johnson & Johnson, GlaxoSmithKline plc., Sanofi, Eli Lilly and Company, Biocon Ltd., Dr. Reddy’s Laboratories Ltd., Merck & Co., Inc., Bayer AG, Amgen, Inc., F. Hoffmann-La Roche Ltd, and Abbott Laboratories.

1 Preface
    1.1 Market Definition and Scope
    1.2 Market Segmentation
    1.3 Key Research Objectives
    1.4 Research Highlights

2 Assumptions and Research Methodology

3 Executive Summary: Global Bioengineered Protein Drugs  Market

4 Market Overview
    4.1 Introduction
          4.1.1 Product Overview
          4.1.2 Industry Evolution / Developments
          4.1.3 Key Market Indicators
    4.2 Market Dynamics 
          4.2.1 Drivers
          4.2.2 Restraints
          4.2.3 Opportunity
    4.3 Market Revenue Projections
    4.4 Porter’s Five Force Analysis
    4.5 Value Chain Analysis
    4.6 Market Outlook

5 Global Bioengineered Protein Drugs  Market Analysis and Forecasts, by Drug Type
    5.1 Key Findings / Developments
    5.2 Introduction & Definition    
    5.3 Market Value Forecast by Drug Type, 2017–2025
          5.3.1 Monoclonal Antibody
                   5.3.1.1 Humira
                   5.3.1.2 Rituxan
                   5.3.1.3 Avastin
                   5.3.1.4 Herceptin
                   5.3.1.5 Remicade
                   5.3.1.6 Lucentis
                   5.3.1.7 Enbrel 
                   5.3.1.8 Synazis
                   5.3.1.9 others
          5.3.2 Therapeutic Proteins Market By Type 
                   5.3.2.1 Hormones
                   5.3.2.2 Cytokines
                             5.3.2.2.1 Neupogen
                             5.3.2.2.2 Neulasta
                             5.3.2.2.3 Interferon Alpha
                             5.3.2.2.4 Erythropoietin Alpha
                             5.3.2.2.5 Interleukin
                             5.3.2.2.6 Others
                   5.3.2.3 Blood Factor
                   5.3.2.4 Enzyme Therapy
                             5.3.2.4.1 Systemic Enzyme Therapy
                             5.3.2.4.2 Digestive Enzyme Therapy
                   5.3.2.5 Thrombolytics
                             5.3.2.5.1 tPA
                             5.3.2.5.2 Streptokinase
                             5.3.2.5.3 Urokinase
                   5.3.2.6 Vaccines
    5.4 Key Trends
    5.5 Market Attractiveness by Drug Type

6 Global Bioengineered Protein Drugs  Market Analysis and Forecasts, by Disease Condition
    6.1 Key Findings / Developments
    6.2 Introduction & Definition
    6.3 Market Value Forecast by Disease Condition, 2017–2025
          6.3.1 Cancer
          6.3.2 Diabetes
          6.3.3 Autoimmune Disorder
          6.3.4 Infectious Disease
          6.3.5 Hematopoiesis
          6.3.6 CVD
          6.3.7 Neurodegenerative
          6.3.8 Others
    6.4 key Trends
    6.5 Market Attractiveness by Disease Condition

7 Global Bioengineered Protein Drugs  Market Analysis and Forecasts, by End-user
    7.1 Key Findings / Developments    
    7.2 Introduction & Definition
    7.3 Market Value Forecast by End-user, 2017–2025
          7.3.1 Pharma and Biotech Companies
          7.3.2 CROs
          7.3.3 Research Institutes
    7.4 Key Trends
    7.5 Market Attractiveness by End-user

8 Global Bioengineered Protein Drugs  Market Analysis and Forecasts, by Region
    8.1 Policies and Regulations
    8.2 Market Value Forecast by Region
          8.2.1 North America 
          8.2.2 Europe 
          8.2.3 Asia Pacific 
          8.2.4 Latin America  
          8.2.5 Middle East & Africa 
    8.3 Market Attractiveness by Region

9 North America Bioengineered Protein Drugs  Market Analysis and Forecasts
    9.1 Market Value Forecast by Country, 2017–2025
          9.1.1 U.S.
          9.1.2 Canada
    9.2 Market Value Forecast by Drug Type, 2017–2025
    9.3 Market Value Forecast by Disease Condition, 2017–2025
    9.4 Market Value Forecast by End - User, 2017–2025
    9.5 Market Attractiveness Analysis 
          9.5.1 By Country
          9.5.2 By Drug Type 
          9.5.3 By Disease Condition 
          9.5.4 By End-user

10 Europe Bioengineered Protein Drugs  Market Analysis and Forecasts
    10.1 Market Value Forecast by Country, 2017–2025
          10.1.1 Germany
          10.1.2 Italy 
          10.1.3 France 
          10.1.4 U.K.
          10.1.5 Spain
          10.1.6 Rest of Europe 
    10.2 Market Value Forecast by Drug Type, 2017–2025
    10.3 Market Value Forecast by Disease Condition, 2017–2025
    10.4 Market Value Forecast by End-user, 2017–2025
    10.5 Market Attractiveness Analysis 
          10.5.1 By Country
          10.5.2 By Drug Type 
          10.5.3 By Disease Condition 
          10.5.4 By End-user

11 Asia Pacific Bioengineered Protein Drugs  Market Analysis and Forecasts
    11.1 Market Value Forecast by Country, 2017–2025
          11.1.1 Japan
          11.1.2 China 
          11.1.3 India
          11.1.4 Rest of APAC
    11.2 Market Value Forecast by Drug Type, 2017–2025
    11.3 Market Value Forecast by Disease Condition, 2017–2025
    11.4 Market Value Forecast by End-user, 2017–2025
    11.5 Market Attractiveness Analysis 
          11.5.1 By Country
          11.5.2 By Drug Type 
          11.5.3 By Disease Condition
          11.5.4 By End-user

12 Latin America Bioengineered Protein Drugs  Market Analysis and Forecasts
    12.1 Market Value Forecast by Country, 2017–2025
          12.1.1 Brazil
          12.1.2 Mexico
          12.1.3 Rest of LATAM     
    12.2 Market Value Forecast by Drug Type, 2017–2025
    12.3 Market Value Forecast by Disease Condition, 2017–2025
    12.4 Market Value Forecast by End-user, 2017–2025
    12.5 Market Attractiveness Analysis 
          12.5.1 By Country
          12.5.2 By Drug Type 
          12.5.3 By Disease Condition 
          12.5.4 By End-user

13 Middle East & Africa Bioengineered Protein Drugs  Market Analysis and Forecasts
    13.1 Market Value Forecast by Country, 2017–2025
          13.1.1 South Africa
          13.1.2 Saudi Arabia
          13.1.3 Rest of MEA 
    13.2 Market Value Forecast by Drug Type, 2017–2025
    13.3 Market Value Forecast by Disease Condition, 2017–2025
    13.4 Market Value Forecast by End-user, 2017–2025
    13.5 Market Attractiveness Analysis 
          13.5.1 By Country
          13.5.2 By Drug Type 
          13.5.3 By Disease Condition
          13.5.4 By End-user

14 Competitive Landscape
    14.1 Market Share Analysis by Company 2016
    14.2 Company Profiles 
          14.2.1 Abbott Laboratories
                   14.2.1.1 Company Details
                   14.2.1.2 Company Description
                   14.2.1.3 Business Overview
                   14.2.1.4 SWOT Analysis
                   14.2.1.5 Financial Analysis
                   14.2.1.6 Strategic Overview
          14.2.2 Amgen Inc. 
                   14.2.2.1 Company Details
                   14.2.2.2 Company Description
                   14.2.2.3 Business Overview
                   14.2.2.4 SWOT Analysis
                   14.2.2.5 Financial Analysis
                   14.2.2.6 Strategic Overview
          14.2.3 Bayer AG
                   14.2.3.1 Company Details
                   14.2.3.2 Company Description
                   14.2.3.3 Business Overview
                   14.2.3.4 SWOT Analysis
                   14.2.3.5 Financial Analysis
                   14.2.3.6 Strategic Overview
          14.2.4 Biocon Ltd.
                   14.2.4.1 Company Details
                   14.2.4.2 Company Description
                   14.2.4.3 Business Overview
                   14.2.4.4 SWOT Analysis
                   14.2.4.5 Financial Analysis
                   14.2.4.6 Strategic Overview
          14.2.5 Dr. Reddy’s Laboratories       
                   14.2.5.1 Company Details
                   14.2.5.2 Company Description
                   14.2.5.3 Business Overview
                   14.2.5.4 SWOT Analysis
                   14.2.5.5 Financial Analysis
                   14.2.5.6 Strategic Overview
          14.2.6 Eli Lilly and Comapny 
                   14.2.6.1 Company Details
                   14.2.6.2 Company Description
                   14.2.6.3 Business Overview
                   14.2.6.4 SWOT Analysis
                   14.2.6.5 Financial Analysis
                   14.2.6.6 Strategic Overview
          14.2.7 F. Hoffmann – La Roche Ltd.
                   14.2.7.1 Company Details
                   14.2.7.2 Company Description
                   14.2.7.3 Business Overview
                   14.2.7.4 SWOT Analysis
                   14.2.7.5 Financial Analysis
                   14.2.7.6 Strategic Overview
          14.2.8 Fresenius kabi
                   14.2.8.1 Company Details
                   14.2.8.2 Company Description
                   14.2.8.3 Business Overview
                   14.2.8.4 SWOT Analysis
                   14.2.8.5 Financial Analysis
                   14.2.8.6 Strategic Overview
          14.2.9 GlaxoSmithKline plc
                   14.2.9.1 Company Details
                   14.2.9.2 Company Description
                   14.2.9.3 Business Overview
                   14.2.9.4 SWOT Analysis
                   14.2.9.5 Financial Analysis
                   14.2.9.6 Strategic Overview
          14.2.10 Johnson & Johnson (Janseen)
                   14.2.10.1 Company Details
                   14.2.10.2 Company Description
                   14.2.10.3 Business Overview
                   14.2.10.4 SWOT Analysis
                   14.2.10.5 Financial Analysis
                   14.2.10.6 Strategic Overview
          14.2.11 Merck & Co., Inc.
                   14.2.11.1 Company Details
                   14.2.11.2 Company Description
                   14.2.11.3 Business Overview
                   14.2.11.4 SWOT Analysis
                   14.2.11.5 Financial Analysis
                   14.2.11.6 Strategic Overview
          14.2.12 Novartis AG
                   14.2.12.1 Company Details
                   14.2.12.2 Company Description
                   14.2.12.3 Business Overview
                   14.2.12.4 SWOT Analysis
                   14.2.12.5 Financial Analysis
                   14.2.12.6 Strategic Overview
          14.2.13 Panacea Biotec
                   14.2.13.1 Company Details
                   14.2.13.2 Company Description
                   14.2.13.3 Business Overview
                   14.2.13.4 SWOT Analysis
                   14.2.13.5 Financial Analysis
                   14.2.13.6 Strategic Overview
          14.2.14 ProBioGen AG
                   14.2.14.1 Company Details
                   14.2.14.2 Company Description
                   14.2.14.3 Business Overview
                   14.2.14.4 SWOT Analysis
                   14.2.14.5 Financial Analysis
                   14.2.14.6 Strategic Overview
          14.2.15 Reliance Life Science Pvt. Ltd.
                   14.2.15.1 Company Details
                   14.2.15.2 Company Description
                   14.2.15.3 Business Overview
                   14.2.15.4 SWOT Analysis
                   14.2.15.5 Financial Analysis
                   14.2.15.6 Strategic Overview
          14.2.16 Sanofi
                   14.2.16.1 Company Details
                   14.2.16.2 Company Description
                   14.2.16.3 Business Overview
                   14.2.16.4 SWOT Analysis
                   14.2.16.5 Financial Analysis
                   14.2.16.6 Strategic Overview

List of Tables

Table 1: Table 1: Global Bioengineered Proteins Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2017–2025
Table 2: Global Monoclonal Antibodies Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 3: Global Therapeutic Proteins Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 4: Global Cytokines Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 5: Global Thrombolytics Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 6: Global Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 7: Global Bioengineered Proteins Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2017–2025
Table 8: Global Bioengineered Proteins Drugs Market Size (US$ Mn) Forecast, by End-users, 2017–2025
Table 9: Global Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Region, 2017–2025
Table 10: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 11: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2017–2025
Table 12: North America Monoclonal Antibody Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 13: North America Therapeutic Protein Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 14: North America Cytokine Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 15: North America Thrombolytics Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 16: North America Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 17: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2017–2025
Table 18: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 19: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 20: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2017–2025
Table 21: Europe Monoclonal Antibody Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 22: Europe Therapeutic Protein Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 23: Europe Cytokines Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 24: Europe Thrombolytics Market Size (US$ Mn) Forecast, by Drug Type (Thrombolytics), 2017–2025
Table 25: Europe Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 26: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2017–2025
Table 27: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 28: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 29: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2017–2025
Table 30: Asia Pacific Monoclonal Antibody Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 31: Asia Pacific Therapeutic Proteins Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 32: Asia Pacific Cytokines Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 33: Asia Pacific Thrombolytics Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 34: Asia Pacific Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 35: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2017–2025
Table 36: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 37: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 38: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2017–2025
Table 39: Latin America Monoclonal Antibody Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 40: Latin America Therapeutic Protein Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 41: Latin America Cytokines Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 42: Latin America Thrombolytics Market Size (US$ Mn) Forecast, by Drug Type (Thrombolytics), 2017–2025
Table 43: Latin America Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 44: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2017–2025
Table 45: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 46: MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 47: MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2017–2025
Table 48: MEA Monoclonal Antibody Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 49: MEA Therapeutic Protein Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 50: MEA Cytokines Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 51: MEA Thrombolytics Market Size (US$ Mn) Forecast, by Drug Type (Thrombolytics), 2017–2025
Table 52: MEA Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 53: MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2017–2025
Table 54: MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 55: India Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2017–2025
Table 56: India Monoclonal Antibody Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 57: India Therapeutic Protein Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 58: India Cytokines Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 59: India Thrombolytics Market Size (US$ Mn) Forecast, by Drug Type (Thrombolytics), 2017–2025
Table 60: India Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 61: India Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2017–2025
Table 62: India Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2017–2025

List of Figures

Figure 1: Global Bioengineered Protein Drugs Market Size (US$ Mn) and Forecast, 2016–2024
Figure 2: Market Value Share, by Drug Type (2016)
Figure 3: Market Value Share, by Disease Condition (2016)
Figure 4: Market Value Share, by End-User (2016)
Figure 5: Market Value Share, by Region (2016)
Figure 6: Global Bioengineered Proteins Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
Figure 7: Global Monoclonal Antibodies Drugs Market Value Share Analysis, by Type, 2016 and 2025
Figure 8: Global Therapeutic Proteins Drugs Market Value Share Analysis, by Type, 2016 and 2025
Figure 9: Global Cytokines Drugs Market Value Share Analysis, by Type, 2016 and 2025
Figure 10: Global Thrombolytics Drugs Market Value Share Analysis, by Type, 2016 and 2025
Figure 11: Global Enzyme Therapy Market Value Share Analysis, by Type, 2016 and 2025
Figure 12: Global Therapeutic Proteins Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 13: Global Monoclonal Antibodies Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 14: Global Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 15: Global Bioengineered Proteins Drugs Market Attractiveness Analysis, by Drug Type
Figure 16: Global Bioengineered Proteins Drugs Market Value Share Analysis, by Disease Condition, 2016 and 2025
Figure 17: Global Cancer Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 18: Global Diabetes Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 19: Global Infectious Disease Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 20: Global Autoimmune Disorders Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 21: Global Hematopoiesis Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 22: Global CVD Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 23: Global Neurodegenerative Disease Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 24: Global Others Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 25: Global Bioengineered Proteins Drugs Market Attractiveness Analysis, by Disease Condition
Figure 26: Global Bioengineered Proteins Drugs Market Value Share Analysis, by End-users, 2016 and 2025
Figure 27: Global Pharmaceutical Companies and Biotechnological Companies Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 28: Global Contract Research Organizations Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017-2025
Figure 29: Global Research Institutes Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 30: Global Bioengineered Proteins Drugs Market Attractiveness Analysis, by End-users
Figure 31: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 32: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 33: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 34: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 35: MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 36: Global Bioengineered Protein Drugs Market Attractiveness Analysis, by Region
Figure 37: U.S. Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 38: Canada Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 39: North America Bioengineered Protein Drugs Market Attractiveness Analysis, by Country
Figure 40: North Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Type
Figure 41: North America Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition
Figure 42: North America Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user
Figure 43: Germany Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 44: France Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 45: U.K. Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 46: Italy Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 47: Spain Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 48: Rest of Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 49: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by Country
Figure 50: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Types
Figure 51: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition
Figure 52: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user
Figure 53: China Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 54: Japan Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 55: India Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 56: Australia Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 57: Rest of APAC Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 58: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by Country
Figure 59: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Types
Figure 60: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition
Figure 61: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user
Figure 62: Brazil Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 63: Mexico Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 64: Rest of LATAM Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 65: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by Country
Figure 66: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Type
Figure 67: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition
Figure 68: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user
Figure 69: GCC Countries Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 70: South Africa Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 71: Rest of MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 72: MEA Bioengineered Protein Drugs Market Attractiveness Analysis, by Country
Figure 73: MEA Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Types
Figure 74: MEA Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition
Figure 75: MEA Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user
Figure 76: India Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 77: India Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Type
Figure 78: India Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition
Figure 79: India Bioengineered Protein Drugs Market Attractiveness Analysis, by End-users
Figure 80: Monoclonal Antibodies Bioengineered Protein Therapeutics Market Share Analysis By Company (2016)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

250

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved